ALK-Abello AS - Company Profile
Powered by 
All the sales intelligence you need on ALK-Abello AS in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how ALK-Abello AS fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with ALK-Abello AS.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
ALK-Abello AS (ALK), a subsidiary of The Lundbeck Foundation, is a specialty pharmaceutical company. The company's main activities include the development, production, and marketing of allergy immunotherapy and anaphylaxis treatments. Its products consist of tablets, sublingual or drop-based vaccines, subcutaneous vaccines, and adrenaline auto-injectors to treat severe allergic reactions in emergencies (anaphylaxis). ALK’s research and development pipeline products include sublingual immunotherapy tablets for addressing ragweed, house dust mite, and tree pollen allergy. The company’s products target allergies caused by grass, tree, ragweed, house dust mite, Japanese cedar, and venom. It offers the products in Europe, North America, and Asia-Pacific to pharmaceuticals and healthcare professionals. ALK is headquartered in Horsholm, Denmark.
Headquarters
Denmark
Address
Boege Alle 6-8, Hoersholm, 2970
Website
www.alk.net
Telephone
45 457 47576
No of Employees
2,721
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ALK B (CPH)
Revenue (2024)
$954.2M
14%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
46.9%
(2024 vs 2023)
Market Cap*
$8.2B
Net Profit Margin (2024)
XYZ
28.8%
(2024 vs 2023)
* As of and is in US$
ALK-Abello AS premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Tablets | Acarizax |
| Sublingual or Drop-Based Vaccines | Grastek |
| Subcutaneous Vaccines | Grazax |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In April, the company's neffy 2 mg for the emergency treatment of allergic reactions, was approved by Health Canada, as the first needle-free anaphylaxis treatment of adults and children in Canada. |
| 2025 | Contracts/Agreements | In September, the company entered into an agreement with GenSci to expand the AIT market in China. |
| 2025 | New Product Approvals | In March, the company received approval from Health Canada to offer ACARIZAX, a tablet for use in children, aged five to 11, with house dust mite (HDM) allergy. |
Competitor Comparison
| Key Parameters | ALK-Abello AS | Fagron NV | Nippon Shinyaku Co Ltd | Allergy Therapeutics Plc | Allergopharma GmbH & Co KG |
|---|---|---|---|---|---|
| Headquarters | Denmark | Belgium | Japan | United Kingdom | Germany |
| City | Hoersholm | Nazareth | Kyoto | Worthing | Reinbek |
| State/Province | - | - | Kyoto | England | Schleswig-Holstein |
| No. of Employees | 2,721 | 4,297 | 2,243 | 584 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Peter Halling | Chief Executive Officer; President | Senior Management | 2024 | 49 |
| Claus Steensen Solje | Chief Financial Officer; Executive Vice President | Senior Management | 2023 | 54 |
| Anders Hedegaard | Chairman | Non Executive Board | 2020 | 66 |
| Lene Skole | Vice Chairman | Executive Board | 2015 | 67 |
| Lika Thiesen | Executive Vice President - Global People & Organisation | Senior Management | 2024 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer